Press Releases

10.18.2025

PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer

10.14.2025

TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial

10.13.2025

Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025

10.09.2025

Pfizer Declares Fourth-Quarter 2025 Dividend

09.30.2025

Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients

09.25.2025

Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025

09.23.2025

Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts

09.22.2025

Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio

09.08.2025

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

08.27.2025

Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

08.12.2025

PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery

08.05.2025

Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance